Bendamustine

Generic Name
Bendamustine
Brand Names
Belrapzo, Bendeka, Treanda, Vivimusta
Drug Type
Small Molecule
Chemical Formula
C16H21Cl2N3O2
CAS Number
16506-27-7
Unique Ingredient Identifier
9266D9P3PQ
Background

Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.

Indication

Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions
Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
Associated Therapies
-

A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

First Posted Date
2016-11-03
Last Posted Date
2022-02-18
Lead Sponsor
Millennium Pharmaceuticals, Inc.
Target Recruit Count
43
Registration Number
NCT02954406
Locations
🇺🇸

West Virginia University, Morgantown, West Virginia, United States

🇺🇸

Cedars-Sinai Medical Center (CSMC) - Samuel Oschin Comprehensive Cancer Institute, West Hollywood, California, United States

🇺🇸

University of Arizona Cancer Center, Tucson, Tucson, Arizona, United States

and more 10 locations

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

First Posted Date
2016-11-01
Last Posted Date
2020-12-17
Lead Sponsor
Pfizer
Target Recruit Count
29
Registration Number
NCT02951156
Locations
🇦🇺

Monash Health, Clayton, Victoria, Australia

🇮🇹

Istituto Clinico Humanitas, Rozzano, MI, Italy

🇺🇸

City of Hope, Duarte, California, United States

and more 26 locations

BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma

First Posted Date
2016-07-19
Last Posted Date
2016-07-19
Lead Sponsor
Pusan National University Hospital
Target Recruit Count
20
Registration Number
NCT02836639
Locations
🇰🇷

Pusan National University Hospital, Busan, Korea, Republic of

GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia

First Posted Date
2016-06-14
Last Posted Date
2020-11-23
Lead Sponsor
St. Petersburg State Pavlov Medical University
Target Recruit Count
27
Registration Number
NCT02799147
Locations
🇷🇺

First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation

CyBeR Association in Relapsed/Refractory DLBCL

First Posted Date
2016-05-03
Last Posted Date
2016-05-04
Lead Sponsor
University Hospital, Caen
Target Recruit Count
78
Registration Number
NCT02758925

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

First Posted Date
2016-04-11
Last Posted Date
2023-11-18
Lead Sponsor
Celgene
Target Recruit Count
106
Registration Number
NCT02733042
Locations
🇺🇸

Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

🇺🇸

Jefferson Medical Oncology Associates, Philadelphia, Pennsylvania, United States

🇫🇷

Centre Hospitalier Universitaire d'Avicennes, Bobigny Cedex, France

and more 62 locations

Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma

First Posted Date
2016-04-05
Last Posted Date
2023-11-01
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
18
Registration Number
NCT02728531
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)

First Posted Date
2016-02-23
Last Posted Date
2020-06-11
Lead Sponsor
German CLL Study Group
Target Recruit Count
66
Registration Number
NCT02689141
Locations
🇩🇪

German CLL Study Group, Cologne, Germany

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

First Posted Date
2015-12-10
Last Posted Date
2024-12-11
Lead Sponsor
Bayer
Target Recruit Count
551
Registration Number
NCT02626455
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center- Bergen, New York, New York, United States

🇧🇷

Hospital de Clinicas de Porto Alegre | Clinical Research Center - Surgery Research Center, Porto Alegre, Rio Grande Do Sul, Brazil

🇧🇷

Irmandade da Santa Casa de Misericordia de Porto Alegre | Hospital Sao Francisco - Centro Medico Pesquisa Clinica Cardiologia, Porto Alegre, Rio Grande Do Sul, Brazil

and more 198 locations
© Copyright 2024. All Rights Reserved by MedPath